Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

In This Article:

The TotalSeq Phenocyte solution supports robust study of cellular heterogeneity and rare cell types in complex samples at a single cell level

SAN DIEGO, November 19, 2024--(BUSINESS WIRE)--Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (NYSE: RVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences’ Quantum Barcoding technology platform and BioLegend’s TotalSeqTM antibody conjugates.

While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples.

"By leveraging TotalSeq antibodies and a single-cell genomics-based workflow, this product supports the identification of low frequency events within a cell population. This allows for the study of many more markers than could be observed in a single experiment using other cell analysis technologies to study cell populations," said Craig Monell, senior vice president, reagents, Revvity. "Even with capital-intensive high parameter cytometry tools, we are not able to scale the same level of detection of rare cell types as we can with the TotalSeq Phenocyte solution."

"Scale Bio is focused on leveraging the power of our new Quantum Barcoding technology to enable researchers to dramatically scale up their research by being able to explore more cells, more samples, across more modalities, with simple workflows and an accessible price point. This is just the first of many Scale Bio offerings that will leverage our powerful single cell omics platform to enable more single cell omics insights," said Giovanna Prout, president and CEO of Scale Bio. "The launch of the TotalSeq Phenocyte solution, made available through our collaboration with BioLegend, is the first time we’ve collaborated with another company to bring together disparate technologies into a single solution that supports our customers in upleveling their immunology and oncology research."

The new offering builds upon BioLegend’s well validated TotalSeq-ATM antibody panels and Scale Bio’s Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation.

Waiting for permission
Allow microphone access to enable voice search

Try again.